Core Insights - INNOVATE Corp. announced that its investment in MediBeacon Inc. has led to the recognition of a peer-reviewed article on transdermal GFR measurement as one of the top five Editor's Choice articles for 2025 by the Journal of the American Society of Nephrology [1][2] Company Overview - INNOVATE Corp. operates in three key areas: Infrastructure, Life Sciences, and Spectrum, employing approximately 3,100 people across its subsidiaries [3] - MediBeacon Inc. specializes in fluorescent tracer agents and transdermal detection technology, holding over 55 granted U.S. patents and more than 250 patents worldwide [4] Product and Technology - The MediBeacon® TGFR™ System includes Lumitrace® (relmapirazin) injection, a reusable sensor, and a monitor, enabling kidney function assessment through transdermal measurement of the clearance rate of the fluorescent agent [7] - Lumitrace® is a non-radioactive, non-iodinated compound designed for GFR tracing, with its fluorescence data collected via a sensor placed on the skin [5] - The TGFR System is approved for human use and is being deployed in key medical centers for applications such as heart failure monitoring and oncology drug dosing [6][2] Clinical Significance - There is a significant clinical need for improved GFR assessment at the point of care, with the transdermal GFR (tGFR) method viewed as a potential game changer in clinical practice [2] - The TGFR System aims to address the limitations of existing GFR assessment methodologies, providing vital measurements of kidney function [2]